BioGend Therapeutics Co (ROCO:6733) Gross-Profit-to-Asset % : 11.36% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioGend Therapeutics Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BioGend Therapeutics Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was NT$117.2 Mil. BioGend Therapeutics Co's average Total Assets over the quarter that ended in Mar. 2024 was NT$1,031.8 Mil. Therefore, BioGend Therapeutics Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 11.36%.

BioGend Therapeutics Co Gross-Profit-to-Asset % Historical Data

The historical data trend for BioGend Therapeutics Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGend Therapeutics Co Gross-Profit-to-Asset % Chart

BioGend Therapeutics Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.03

0.11

0.35

2.47

9.57

BioGend Therapeutics Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															3.21	11.51	5.55	12.78	11.36

Competitive Comparison of BioGend Therapeutics Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, BioGend Therapeutics Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGend Therapeutics Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BioGend Therapeutics Co's Gross-Profit-to-Asset % falls into.

BioGend Therapeutics Co Gross-Profit-to-Asset % Calculation

BioGend Therapeutics Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	89.618	/	( (821.822	+	1050.481)	/ 2 )
	=	89.618	/	936.1515
	=	9.57 %

BioGend Therapeutics Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	117.192	/	( (1050.481	+	1013.035)	/ 2 )
	=	117.192	/	1031.758
	=	11.36 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

BioGend Therapeutics Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BioGend Therapeutics Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGend Therapeutics Co (ROCO:6733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioGend Therapeutics Co Ltd (ROCO:6733) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th Floor, Number 3, Park Street, Nangang District, Taipei, TWN, 115

Website

https://www.biogend.com.tw

BioGend Therapeutics Co Ltd is a Taiwan based company involved in developing regenerative bio-orthopaedic medicine to advance the clinical science of maintaining healthy joints in skeletal system. The Company is primarily engaged in the research and development of bone medical device related products. Its products under development include Big-001, Big-006 and Big-009.

BioGend Therapeutics Co (ROCO:6733) Headlines

No Headlines